In the current study, the cogency of cotargeting CDK4/6 and mTOR simultaneously in HNSCC cell lines was confirmed by significant increases in growth inhibition which was observed following treatment with the everolimus in combination with LY2835219 compared with either agent alone. Here, CDK4 is linked to head and neck squamous cell carcinoma.